Table II.
Baseline and treatment characteristics of low-prognosis women stratified according to the POSEIDON criteria ( Poseidon group et al., 2016 ).
| POSEIDON 1 | POSEIDON 2 | POSEIDON 3 | POSEIDON 4 | ||||
|---|---|---|---|---|---|---|---|
| All low-prognosis women (n = 551) | Subgroup 1a; younger unexpected poor responder (n = 38) | Subgroup 1b; younger unexpected suboptimal responder (n = 179) | Subgroup 2a; older unexpected poor responder (n = 41) | Subgroup 2b; older unexpected suboptimal responder (n = 102) | Younger expected poor responder (n = 65) | Older expected poor responder (n = 126) | |
| Baseline characteristics | |||||||
| Female age (years) | 34.4 (4.5) | 30.5 (2.7) | 30.6 (2.8) | 37.9 (2.0) | 37.7 (2.1) | 31.3 (2.7) | 38.7 (2.2) |
| Infertility duration (years) | 2.7 (1.8) | 2.8 (2.0) | 2.7 (1.5) | 2.8 (2.0) | 2.7 (2.1) | 2.9 (1.4) | 2.7 (2.1) |
| Body weight (kg) | 71 (14) | 81 (15) | 70 (13) | 74 (15) | 67 (13) | 72 (12) | 71 (14) |
| Smoking (yes/no) | 102 (18.5) | 11 (29) | 37 (20.7) | 7 (17) | 12 (11.8) | 11 (17) | 24 (19.0) |
| Primary infertility | 319 (57.9) | 30 (79) | 123 (68.7) | 18 (44) | 45 (44.1) | 47 (72) | 56 (44.4) |
| Cause of infertility | |||||||
| Unexplained | 209 (37.9) | 8 (21) | 52 (29.1) | 14 (34) | 47 (46.1) | 12 (19) | 76 (60.3) |
| Tubal factor | 49 (8.9) | 2 (5) | 12 (6.7) | 7 (17) | 13 (12.7) | 9 (14) | 6 (4.8) |
| Endometriosis | 18 (3.3) | 0 (0) | 9 (5.0) | 1 (2) | 3 (2.9) | 2 (3) | 3 (2.4) |
| Male factor | 297 (53.9) | 30 (79) | 116 (64.8) | 21 (51) | 44 (43.1) | 42 (65) | 44 (34.9) |
| AFC, median (IQR) | 12 (6) | 13 (5) | 13 (4) | 12 (3) | 12 (5) | 9 (5) | 8 (5) |
| AMH, median (IQR) | 1.32 (1.36) | 1.98 (1.34) | 2.00 (1.10) | 1.31 (0.45) | 1.95 (0.78) | 0.69 (0.21) | 0.55 (0.39) |
| Treatment characteristics | |||||||
| ICSI | 237 (43.0) | 27 (71) | 101 (56.4) | 12 (29) | 31 (30.4) | 31 (48) | 35 (27.8) |
| GnRH agonist | 414 (75.1) | 28 (74) | 140 (78.2) | 22 (54) | 76 (74.5) | 53 (82) | 95 (75.4) |
| No. of fresh cycles/woman | 2.0 (1.0) | 2.1 (0.9) | 1.8 (0.9) | 2.5 (1.1) | 2.0 (0.9) | 2.0 (0.9) | 2.3 (1.1) |
| No. of FET cycles/woman | 0.6 (1.1) | 0.3 (0.7) | 0.7 (1.2) | 0.6 (0.9) | 1.0 (1.3) | 0.5 (1.0) | 0.3 (0.7) |
| First cycle cancellation | 93 (16.9) | 16 (42) | 0 | 19 (46) | 0 | 15 (23) | 43 (34.1) |
| FSH dose increased between cycle 1 and 2 | 194/351 (55.3) | 24/27 (89) | 21/94 (22.3) | 31/34 (91) | 13/63 (20.6) | 32/42 (76) | 73/91 (80.2) |
| Amount of increase (IU/L) | 56 (25) | 61 (29) | 51 (11) | 57 (46) | 57 (13) | 54 (11) | 57 (19) |
Data are presented as mean (SD) or number (%) unless otherwise specified. AFC, antral follicle count (2–10 mm); AMH, anti-Müllerian hormone (ng/ml); IQR, interquartile range; FET, frozen-thawed embryo transfer.